Navigation Links
DiagnoCure to host Q2 2008 earnings conference call and webcast
Date:6/5/2008

Ticker Symbol: CUR

QUEBEC CITY, June 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its second quarter 2008 financial results on June 13, 2008, at approximately 4:30 p.m. (ET). This release wil be followed by a conference call, which will be held on Monday, June 16, 2008, at 10:00 a.m. (ET). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live on DiagnoCure's website at http://www.diagnocure.com through a link on the Investors page - Presentations and Conferences.

For those who wish to take part in the conference call for the Q&A period, please dial (514) 807-8791 (Montreal area), (416) 644-3414 (Toronto area) or the toll-free number (800) 733-7571.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of June 17, 2008, also through a link on the Investors page - Presentations and Conferences.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit http://www.diagnocure.com.

Forwardlooking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ material y from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.


'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. Shamir Optical Industry Ltd. to Host Conference Call Announcing First Quarter 2008 Earnings Results
3. Mesa Labs Reports Record Year End Sales and Earnings
4. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
5. The Female Health Company Reports 267% Increase in Second Quarter Earnings
6. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
7. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
8. Met-Pro Corporation to Report First Quarter Earnings on May 22
9. Mental Illness Costs U.S. Billions in Lost Earnings
10. The Ensign Group, Inc. Reports First Quarter 2008 Earnings
11. Webcast Alert: Medial Saude S/A Announces First Quarter 2008 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: